Search

Your search keyword '"Aringer M."' showing total 877 results
Start Over Author "Aringer M."
877 results on '"Aringer M."'

3. Entwicklung von Qualitätsstandards für die Versorgung von Patient*innen mit rheumatoider Arthritis zur Anwendung in Deutschland

Author

Kiltz, U., Buschhorn-Milberger, V., Albrecht, K., Lakomek, H.-J., Lorenz, H.-M., Rudwaleit, M., Schneider, M., Schulze-Koops, H., Aringer, M., Hasenbring, M. I., Herzer, P., von Hinüber, U., Krüger, K., Lauterbach, A., Manger, B., Oltman, R., Schuch, F., Schmale-Grede, R., Späthling-Mestekemper, S., Zinke, S., and Braun, J.

Published
2022
Full Text
View/download PDF

6. Effects of nintedanib in patients with limited cutaneous systemic sclerosis and interstitial lung disease

Author

Allanore, Y., Khanna, D., Smith, V., Aringer, M., Hoffmann-Vold, A.M., Kuwana, M., Merkel, P.A., Stock, C., Vonk, M.C., Sambevski, S., Denton, C.P., Allanore, Y., Khanna, D., Smith, V., Aringer, M., Hoffmann-Vold, A.M., Kuwana, M., Merkel, P.A., Stock, C., Vonk, M.C., Sambevski, S., and Denton, C.P.

Abstract

Contains fulltext : 305344.pdf (Publisher’s version ) (Open Access), OBJECTIVES: To investigate the course of interstitial lung disease (ILD) and the effects of nintedanib in patients with limited cutaneous systemic sclerosis (lcSSc). METHODS: In the SENSCIS trial, patients with SSc-ILD were randomized to receive nintedanib or placebo. Patients who completed the SENSCIS trial were eligible to enter SENSCIS-ON, in which all patients received open-label nintedanib. RESULTS: Among 277 patients with lcSSc treated in the SENSCIS trial, the rate (s.e.) of decline in forced vital capacity (FVC; ml/year) over 52 weeks was -74.5 (19.2) in the placebo group and -49.1 (19.8) in the nintedanib group (difference: 25.3 [95% CI -28.9, 79.6]). Among 249 patients with data at week 52, mean (s.e.) change in FVC at week 52 was -86.4 (21.1) ml in the placebo group and -39.1 (22.2) ml in the nintedanib group. Among 183 patients with lcSSc who participated in SENSCIS-ON and had data at week 52, mean (s.e.) change in FVC from baseline to week 52 of SENSCIS-ON was -41.5 (24.0) ml in patients who took placebo in the SENSCIS trial and initiated nintedanib in SENSCIS-ON and -45.1 (19.1) ml in patients who took nintedanib in the SENSCIS trial and continued it in SENSCIS-ON. CONCLUSION: Patients with lcSSc may develop progressive fibrosing ILD. By targeting pulmonary fibrosis, nintedanib slows decline in lung function in patients with lcSSc and ILD. TRIAL REGISTRATION: ClinicalTrials.gov (https://clinicaltrials.gov), NCT02597933 and NCT03313180.

Published
2024

16. POS1090 IMPLEMENTATION OF QUALITY STANDARDS FOR HEALTH CARE OF PATIENTS WITH RHEUMATOID ARTHRITIS: FIRST RESULTS FROM THE NATIONAL DATABASE OF THE GERMAN COLLABORATIVE ARTHRITIS CENTRES

Author

Albrecht, K., primary, Thiele, K., additional, Aringer, M., additional, Callhoff, J., additional, Karberg, K., additional, Krueger, K., additional, Lakomek, J., additional, Lorenz, H. M., additional, Rudwaleit, M., additional, Schmale-Grede, R., additional, Schneider, M., additional, Spaethling-Mestekemper, S., additional, Specker, C., additional, Zinke, S., additional, Braun, J., additional, and Kiltz, U., additional

Published
2023
Full Text
View/download PDF

17. S2k-Leitlinie: Indikation Knieendoprothese: Evidenz- und konsensbasierte Indikationsstellung in der Knie-Endoprothetik (EKIT-Knie)

Author

Lützner, J., Lange, T., Schmitt, J., Kopkow, C., Aringer, M., DGRh, Böhle, E., ZVK, Bork, H., DGOU, Dreinhöfer, K., DNVF, Friederich, N., Deutsche Arthrose-Hilfe e. V., Gravius, S., DGOOC, Heller, K.-D., BVOU, Hube, R., DKG, Gromnica-Ihle, E., Deutsche Rheuma-Liga Bundesverband e. V., Kirschner, S., AE, Kladny, B., DGOU, Kremer, M., DGU, Linke, M., Deutsche Gesellschaft für Medizinische Psychologie, Malzahn, J., AOK Bundesverband, Sabatowski, R., Deutsche Schmerzgesellschaft e. V., Scharf, H.-P., Stöve, J., Wagner, R., DGORh, and Günther, K.-P.

Published
2018
Full Text
View/download PDF

18. Sicherheit und Wirksamkeitshinweise zum Off-label-Einsatz von Biologikatherapien nach Versagen konventioneller Therapien bei Patienten mit entzündlich rheumatischen Erkrankungen: Ergebnisse eines nationalen Registers (GRAID2)

Author

Proft, F., Schulze-Koops, H., Grunke, M., Schrezenmeier, E., Halleck, F., Henes, J., Unger, L., Schmidt, E., Fiehn, C., Jacobi, A., Iking-Konert, C., Kneitz, C., Schmidt, R. E., Bannert, B., Voll, R. E., Fischer-Betz, R., Kötter, I., Tony, H. P., Holle, J., Aringer, M., Erler, A., Behrens, F., Burmester, G. R., and Dörner, T.

Published
2018
Full Text
View/download PDF

21. Rheumatoide Arthritis/chronische Polyarthritis heute

Author

Leuchten, N. and Aringer, M.

Abstract

Zusammenfassung: Fortschritte in der medikamentösen Basistherapie der rheumatoiden Arthritis, v. a. die Behandlung mit Methotrexat und mit Biologika, haben aus einer chronisch voranschreitenden Erkrankung mit hoher Invalidität und Letalität ein fast immer gut kontrollierbares Krankheitsbild gemacht. Um irreversible Schäden zu vermeiden, ist eine frühe Diagnose entscheidend: Maximal 3 Monate dürfen von Beschwerdebeginn bis zum Beginn der Basistherapie vergehen – eine klinische und organisatorische Herausforderung, die zu meistern ist. Die langfristige Therapie wird mit standardisierten Verlaufsscores überwacht und bei nicht suffizientem Erfolg konsequent angepasst. Schmerztherapie, Physio- und Ergotherapie und „Rheuma-Chirurgie“ spielen wesentliche Rollen im Management der rheumatoiden Arthritis. Ein konsequentes multimodales Therapieregime kann den Krankheitsverlauf entscheidend verändern und Spätschäden verhindern oder auf ein Minimalmaß reduzieren.

Published
2024
Full Text
View/download PDF

22. Poursuite du traitement par le nintédanib chez les patients atteints de sclérodermie systémique cutanée limitée (SCSCL) et de pneumopathie interstitielle diffuse (PID)

Author

Allanore, Y., primary, Khanna, D., additional, Smith, V., additional, Aringer, M., additional, Hoffmann-Vold, A.M., additional, Kuwana, M., additional, Merkel, P.A., additional, James, A., additional, Sambeski, S., additional, Alves, M., additional, and Denton, C.P., additional

Published
2022
Full Text
View/download PDF

27. Entzündliche Gelenkerkrankungen

Author

Machold, K. P., Kiener, H. P., Redlich, K., Scheinecker, C., Siegmeth, W., Huemer, Ch., Dunky, A., Hermann, J., Winkler, H., Lindner, E., Schirmer, M., Thumb, N., Thonhofer, R., Dejaco, Ch., Duftner, Ch., Graninger, W., Mirus, S., Ebner, W., Holinka, J., Wanivenhaus, A., Grohs, J. G., Yazdani-Biuki, B., Stummvoll, G., Aringer, M., Aletaha, D., Petera, P., Steindl, M., Nothnagl, Th., Leeb, B. F., Stradner, M. H., Kolarz, G., Sautner, J., Dunky, Attila, editor, Graninger, Winfried, editor, Herold, Manfred, editor, Smolen, Josef, editor, and Wanivenhaus, Axel, editor

Published
2012
Full Text
View/download PDF

28. Andere Erkrankungen

Author

Herold, M., Bröll, H., Aringer, M., Graninger, W., Granitz, Ch., Stuby, U., Sepp, N., Zauner, D., Dunky, Attila, editor, Graninger, Winfried, editor, Herold, Manfred, editor, Smolen, Josef, editor, and Wanivenhaus, Axel, editor

Published
2012
Full Text
View/download PDF

29. ACE inhibitors in SSc patients display a risk factor for scleroderma renal crisis—a EUSTAR analysis

Author

Bütikofer L, Varisco PA, Distler O, Kowal-Bielecka O, Allanore Y, Riemekasten G, Villiger PM, Adler S, Avouac J, Walker UA, Guiducci S, Airò P, Hachulla E, Valentini G, Carreira PE, Cozzi F, Gurman AB, Braun-Moscovici Y, Damjanov N, Ananieva LP, Scorza R, Jimenez S, Busquets J, Li M, Müller-Ladner U, Maurer B, Tyndall A, Lapadula G, Iannone F, Becvar R, Sierakowsky S, Bielecka OK, Cutolo M, Sulli A, Cuomo G, Vettori S, Rednic S, Nicoara I, Vlachoyiannopoulos P, Montecucco C, Caporali R, Novak S, Czirják L, Varju C, Chizzolini C, Kucharz EJ, Kotulska A, Kopec-Medrek M, Widuchowska M, Rozman B, Mallia C, Coleiro B, Gabrielli A, Farge D, Hij A, Hesselstrand R, Scheja A, Wollheim F, Martinovic D, Govoni M, Monaco AL, Hunzelmann N, Pellerito R, Bambara LM, Caramaschi P, Black C, Denton C, Henes J, Santamaria VO, Heitmann S, Krasowska D, Seidel M, Oleszowsky M, Burkhardt H, Himsel A, Salvador MJ, Stamenkovic B, Stankovic A, Tikly M, Starovoytova MN, Engelhart M, Strauss G, Nielsen H, Damgaard K, Szücs G, Mendoza AZ, de la Puente Buijdos C, Sifuentes Giraldo WA, Midtvedt Ø, Garen T, Launay D, Valesini G, Riccieri V, Ionescu RM, Opris D, Groseanu L, Wigley FM, Mihai CM, Cornateanu RS, Ionitescu R, Gherghe AM, Gorga M, Dobrota R, Bojinca M, Schett G, Distler JHW, Meroni P, Zeni S, Mouthon L, De Keyser F, Smith V, Cantatore FP, Corrado A, Ullman S, Iversen L, Pozzi MR, Eyerich K, Hein R, Knott E, Szechinski J, Wiland P, Szmyrka-Kaczmarek M, Sokolik R, Morgiel E, Krummel-Lorenz B, Saar P, Aringer M, Günther C, Anic B, Baresic M, Mayer M, Radominski SC, de Souza Müller C, Azevedo VF, Agachi S, Groppa L, Chiaburu L, Russu E, Zenone T, Stebbings S, Highton J, Stamp L, Chapman P, Baron M, O'Donnell J, Solanki K, Doube A, Veale D, O'Rourke M, Loyo E, Rosato E, Pisarri S, Tanaseanu CM, Popescu M, Dumitrascu A, Tiglea I, Chirieac R, Ancuta C, Furst DE, Kafaja S, de la Peña Lefebvre PG, Rubio SR, Exposito MV, Sibilia J, Chatelus E, Gottenberg JE, Chifflot H, Litinsky I, Venalis A, Butrimiene I, Venalis P, Rugiene R, Karpec D, Kerzberg E, Montoya F, Cosentino V, Castellvi I., Publica, Bütikofer, L, Varisco, Pa, Distler, O, Kowal-Bielecka, O, Allanore, Y, Riemekasten, G, Villiger, Pm, Adler, S, Avouac, J, Walker, Ua, Guiducci, S, Airò, P, Hachulla, E, Valentini, G, Carreira, Pe, Cozzi, F, Gurman, Ab, Braun-Moscovici, Y, Damjanov, N, Ananieva, Lp, Scorza, R, Jimenez, S, Busquets, J, Li, M, Müller-Ladner, U, Maurer, B, Tyndall, A, Lapadula, G, Iannone, F, Becvar, R, Sierakowsky, S, Bielecka, Ok, Cutolo, M, Sulli, A, Cuomo, G, Vettori, S, Rednic, S, Nicoara, I, Vlachoyiannopoulos, P, Montecucco, C, Caporali, R, Novak, S, Czirják, L, Varju, C, Chizzolini, C, Kucharz, Ej, Kotulska, A, Kopec-Medrek, M, Widuchowska, M, Rozman, B, Mallia, C, Coleiro, B, Gabrielli, A, Farge, D, Hij, A, Hesselstrand, R, Scheja, A, Wollheim, F, Martinovic, D, Govoni, M, Monaco, Al, Hunzelmann, N, Pellerito, R, Bambara, Lm, Caramaschi, P, Black, C, Denton, C, Henes, J, Santamaria, Vo, Heitmann, S, Krasowska, D, Seidel, M, Oleszowsky, M, Burkhardt, H, Himsel, A, Salvador, Mj, Stamenkovic, B, Stankovic, A, Tikly, M, Starovoytova, Mn, Engelhart, M, Strauss, G, Nielsen, H, Damgaard, K, Szücs, G, Mendoza, Az, de la Puente Buijdos, C, Sifuentes Giraldo, Wa, Midtvedt, Ø, Garen, T, Launay, D, Valesini, G, Riccieri, V, Ionescu, Rm, Opris, D, Groseanu, L, Wigley, Fm, Mihai, Cm, Cornateanu, R, Ionitescu, R, Gherghe, Am, Gorga, M, Dobrota, R, Bojinca, M, Schett, G, Distler, Jhw, Meroni, P, Zeni, S, Mouthon, L, De Keyser, F, Smith, V, Cantatore, Fp, Corrado, A, Ullman, S, Iversen, L, Pozzi, Mr, Eyerich, K, Hein, R, Knott, E, Szechinski, J, Wiland, P, Szmyrka-Kaczmarek, M, Sokolik, R, Morgiel, E, Krummel-Lorenz, B, Saar, P, Aringer, M, Günther, C, Anic, B, Baresic, M, Mayer, M, Radominski, Sc, de Souza Müller, C, Azevedo, Vf, Agachi, S, Groppa, L, Chiaburu, L, Russu, E, Zenone, T, Stebbings, S, Highton, J, Stamp, L, Chapman, P, Baron, M, O'Donnell, J, Solanki, K, Doube, A, Veale, D, O'Rourke, M, Loyo, E, Rosato, E, Pisarri, S, Tanaseanu, Cm, Popescu, M, Dumitrascu, A, Tiglea, I, Chirieac, R, Ancuta, C, Furst, De, Kafaja, S, de la Peña Lefebvre, Pg, Rubio, Sr, Exposito, Mv, Sibilia, J, Chatelus, E, Gottenberg, Je, Chifflot, H, Litinsky, I, Venalis, A, Butrimiene, I, Venalis, P, Rugiene, R, Karpec, D, Kerzberg, E, Montoya, F, Cosentino, V, and Castellvi, I.

Subjects
INVOLVEMENT, Male, Hypertension, Renal, ACE inhibitors, lcsh:Diseases of the musculoskeletal system, Scleroderma Renal Crisis, MULTICENTER, Angiotensin-Converting Enzyme Inhibitors, Scleroderma, Scleroderma renal crisis, 0302 clinical medicine, Risk Factors, Medicine and Health Sciences, Medicine, 030212 general & internal medicine, Prospective Studies, 610 Medicine & health, Renal, Antihypertensive drugs, Outcome, antihypertensive drugs, arterial hypertension, outcome, scleroderma renal crisis, Incidence (epidemiology), Incidence, Hazard ratio, Acute Kidney Injury, Middle Aged, Europe, Treatment Outcome, Population Surveillance, Cohort, Hypertension, Female, 360 Social problems & social services, Proto-oncogene tyrosine-protein kinase Src, Research Article, Arterial hypertension, medicine.medical_specialty, 03 medical and health sciences, ENDOTHELIN-1, Internal medicine, Humans, Risk factor, Aged, 030203 arthritis & rheumatology, Scleroderma, Systemic, business.industry, SYSTEMIC-SCLEROSIS, Systemic, medicine.disease, Concomitant, lcsh:RC925-935, business
Abstract

Objectives To investigate the effect of ACE inhibitors (ACEi) on the incidence of scleroderma renal crisis (SRC) when given prior to SRC in the prospectively collected cohort from the European Scleroderma Trial and Research Group (EUSTAR). Methods SSc patients without prior SRC and at least one follow-up visit were included and analyzed regarding SRC, arterial hypertension, and medication focusing on antihypertensive medication and glucocorticoids (GC). Results Out of 14,524 patients in the database, we identified 7648 patients with at least one follow-up. In 27,450 person-years (py), 102 patients developed SRC representing an incidence of 3.72 (3.06–4.51) per 1000 py. In a multivariable time-to-event analysis adjusted for age, sex, disease severity, and onset, 88 of 6521 patients developed SRC. The use of ACEi displayed an increased risk for the development of SRC with a hazard ratio (HR) of 2.55 (95% confidence interval (CI) 1.65–3.95). Adjusting for arterial hypertension resulted in a HR of 2.04 (95%CI 1.29–3.24). There was no evidence for an interaction of ACEi and arterial hypertension (HR 0.83, 95%CI 0.32–2.13, p = 0.69). Calcium channel blockers (CCB), angiotensin receptor blockers (ARB), endothelin receptor antagonists, and GC—mostly in daily dosages below 15 mg of prednisolone—did not influence the hazard for SRC. Conclusions ACEi in SSc patients with concomitant arterial hypertension display an independent risk factor for the development of SRC but are still first choice in SRC treatment. ARBs might be a safe alternative, yet the overall safety of alternative antihypertensive drugs in SSc patients needs to be further studied.

Published
2020

32. Europäische Versorgungsstandards für Menschen mit rheumatoider Arthritis: Übersetzung und Kommentierung der von der EULAR unterstützten Vorschläge des eumusc.net durch eine Task Force von DGRh und VRA mit Unterstützung der Deutschen Rheuma-Liga

Author

Braun, J., Krause, A., Aringer, M., Burmester, G., Bessler, F., Engel, J.-M., Faubel, U., Fischer-Betz, R., Genth, E., Gromnica-Ihle, E., Hellmich, B., Kötter, I., Krüger, K., Lakomek, J., Lorenz, H.-M., Manger, B., Märker-Hermann, E., Minden, K., Müller-Ladner, U., Rautenstrauch, J., Rehart, S., Riemekasten, G., Rudwaleit, M., Rüther, W., Schett, G., Schuch, F., Schulze-Koops, H., Specker, C., Wassenberg, S., Wiek, D., Zink, A., and Schneider, M.

Published
2016
Full Text
View/download PDF

38. POS0731 ASSOCIATION OF PATIENT-REPORTED OUTCOMES WITH TYPE I INTERFERON GENE SIGNATURE FROM THE INTERNATIONAL SYSTEMIC LUPUS ERYTHEMATOSUS PROSPECTIVE OBSERVATIONAL COHORT STUDY (SPOCS)

Author

Aringer, M., primary, Arnaud, L., additional, Peschken, C., additional, Furie, R., additional, Morand, E. F., additional, Seo, C., additional, Rapsomaniki, E., additional, Hedberg, J., additional, Knagenhjelm, J., additional, Grünfeld Eén, T., additional, Desta, B., additional, Tummala, R., additional, Sorrentino, A., additional, and Stirnadel-Farrant, H., additional

Published
2022
Full Text
View/download PDF

39. POS0733 DISCORDANCE BETWEEN PATIENT GLOBAL ASSESSMENT AND PHYSICIAN GLOBAL ASSESSMENT OF DISEASE ACTIVITY IN THE MODERATE TO SEVERE SYSTEMIC LUPUS ERYTHEMATOSUS PROSPECTIVE OBSERVATIONAL COHORT STUDY (SPOCS)

Author

Arnaud, L., primary, Furie, R., additional, Morand, E. F., additional, Peschken, C., additional, Aringer, M., additional, Rapsomaniki, E., additional, Hedberg, J., additional, Knagenhjelm, J., additional, Seo, C., additional, Grünfeld Eén, T., additional, Desta, B., additional, Sorrentino, A., additional, Tummala, R., additional, and Stirnadel-Farrant, H., additional

Published
2022
Full Text
View/download PDF

42. 2021 DORIS definition of remission in SLE: Final recommendations from an international task force.

Author

van Vollenhoven R.F., Bertsias G., Doria A., Isenberg D., Morand E., Petri M.A., Pons-Estel B.A., Rahman A., Ugarte-Gil M.F., Voskuyl A., Arnaud L., Bruce I.N., Cervera R., Costedoat-Chalumeau N., Gordon C., Houssiau F.A., Mosca M., Schneider M., Ward M.M., Alarcon G., Aringer M., Askenase A., Bae S.-C., Bootsma H., Boumpas D.T., Brunner H., Clarke A.E., Coney C., Czirjak L., Dorner T., Faria R., Fischer R., Fritsch-Stork R., Inanc M., Jacobsen S., Jayne D., Kuhn A., van Leeuw B., Limper M., Mariette X., Navarra S., Nikpour M., Olesinska M.H., Pons-Estel G., Romero-Diaz J., Rubio B., Schoenfeld Y., Bonfa E., Smolen J., Teng Y.K.O., Tincani A., Tsang-A-Sjoe M., Vasconcelos C., Voss A., Werth V.P., Zakharhova E., Aranow C., van Vollenhoven R.F., Bertsias G., Doria A., Isenberg D., Morand E., Petri M.A., Pons-Estel B.A., Rahman A., Ugarte-Gil M.F., Voskuyl A., Arnaud L., Bruce I.N., Cervera R., Costedoat-Chalumeau N., Gordon C., Houssiau F.A., Mosca M., Schneider M., Ward M.M., Alarcon G., Aringer M., Askenase A., Bae S.-C., Bootsma H., Boumpas D.T., Brunner H., Clarke A.E., Coney C., Czirjak L., Dorner T., Faria R., Fischer R., Fritsch-Stork R., Inanc M., Jacobsen S., Jayne D., Kuhn A., van Leeuw B., Limper M., Mariette X., Navarra S., Nikpour M., Olesinska M.H., Pons-Estel G., Romero-Diaz J., Rubio B., Schoenfeld Y., Bonfa E., Smolen J., Teng Y.K.O., Tincani A., Tsang-A-Sjoe M., Vasconcelos C., Voss A., Werth V.P., Zakharhova E., and Aranow C.

Abstract

Objective To achieve consensus on a definition of remission in SLE (DORIS). Background Remission is the stated goal for both patient and caregiver, but consensus on a definition of remission has been lacking. Previously, an international task force consisting of patient representatives and medical specialists published a framework for such a definition, without reaching a final recommendation. Methods Several systematic literature reviews were performed and specific research questions examined in suitably chosen data sets. The findings were discussed, reformulated as recommendations and voted on. Results Based on data from the literature and several SLE-specific data sets, a set of recommendations was endorsed. Ultimately, the DORIS Task Force recommended a single definition of remission in SLE, based on clinical systemic lupus erythematosus disease activitiy index (SLEDAI)=0, Evaluator's Global Assessment <0.5 (0-3), prednisolone 5 mg/day or less, and stable antimalarials, immunosuppressives, and biologics. Conclusion The 2021 DORIS definition of remission in SLE is recommended for use in clinical care, education, and research including clinical trials and observational studies.Copyright © 2021 BMJ Publishing Group. All rights reserved.

Published
2022

50. Entwicklung von Qualitätsstandards für die Versorgung von Patient*innen mit rheumatoider Arthritis zur Anwendung in Deutschland

Author

Kiltz, U., primary, Buschhorn-Milberger, V., additional, Albrecht, K., additional, Lakomek, H.-J., additional, Lorenz, H.-M., additional, Rudwaleit, M., additional, Schneider, M., additional, Schulze-Koops, H., additional, Aringer, M., additional, Hasenbring, M. I., additional, Herzer, P., additional, von Hinüber, U., additional, Krüger, K., additional, Lauterbach, A., additional, Manger, B., additional, Oltman, R., additional, Schuch, F., additional, Schmale-Grede, R., additional, Späthling-Mestekemper, S., additional, Zinke, S., additional, and Braun, J., additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results